07:01 AM EDT, 08/18/2025 (MT Newswires) -- Natera ( NTRA ) said Monday that topline results from a phase III clinical trial in muscle-invasive bladder cancer showed a "statistically significant and clinically meaningful improvement" in disease-free and overall survivals for Signatera-positive patients treated with atezolizumab.

The trial uses the Signatera ctDNA test in patients with muscle-invasive bladder cancer to detect molecular residual disease in the bloodstream after surgery and predict who will benefit from adjuvant treatment with the cancer immunotherapy atezolizumab.

The company expects trial data to be presented at an upcoming medical conference.